Journal Article
. 2017 Apr;19(1).
doi: 10.1186/s13058-017-0837-2.

Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65

Suzanne C O'Neill 1 Claudine Isaacs 2 Filipa Lynce 2 Deena Mary Atieh Graham 3 Calvin Chao 4 Vanessa B Sheppard 5 Yingjun Zhou 2 Chunfu Liu 6 Nandini Selvam 7 Marc D Schwartz 2 Arnold L Potosky 2 
Affiliations
  • PMID: 28359319
  •     38 References
  •     1 citations

Abstract

Background: Aside from chemotherapy utilization, limited data are available on the relationship between gene expression profiling (GEP) testing and breast cancer care. We assessed the relationship between GEP testing and additional variables and the outcomes of endocrine therapy initiation, discontinuation and adherence, and breast imaging exams in women under age 65 years.

Methods: Data from five state cancer registries were linked with claims data and GEP results. We assessed variables associated with survivorship care outcomes in an incident cohort of 5014 commercially insured women under age 65 years, newly diagnosed with stage I or II hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2) non-positive breast cancer from 2006 to 2010.

Results: Among tested women, those with high Oncotype DX® Breast Recurrence Score® (RS) were significantly less likely to initiate endocrine therapy than women with low RS tumors (OR 0.40 (95% CI 0.20 to 0.81); P = 0.01). Among all test-eligible women, receipt of Oncotype DX testing was associated with a greater likelihood of endocrine therapy initiation (OR 2.48 (95% CI 2.03 to 3.04); P <0.0001). The odds of initiation were also significantly higher for tested vs. untested women among women who did not initiate chemotherapy within six months of diagnosis (OR 3.25 (95% CI 2.53 to 4.16)), with no effect in women who received chemotherapy. Discontinuation and adherence and breast imaging exams were unrelated to tested status or RS.

Conclusions: Lower endocrine therapy initiation rates among women with high RS tumors and among untested women not receiving chemotherapy are concerning, given its established efficacy. Additional research is needed to suggest mechanisms to close this gap.

Keywords: Breast cancer; Breast imaging; Endocrine therapy; Gene expression profiling; Genomic testing.

Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.
Michael J Hassett, Samuel M Silver, +12 authors, Jane C Weeks.
J Clin Oncol, 2012 May 16; 30(18). PMID: 22585699    Free PMC article.
Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.
Suzanne C O'Neill, Claudine Isaacs, +8 authors, Arnold L Potosky.
J Natl Compr Canc Netw, 2015 Oct 21; 13(10). PMID: 26483061    Free PMC article.
Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer.
Christopher R Friese, T May Pini, +8 authors, Jennifer J Griggs.
Breast Cancer Res Treat, 2013 Apr 02; 138(3). PMID: 23542957    Free PMC article.
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.
Jennifer C Livaudais, Dawn L Hershman, +7 authors, Gloria D Coronado.
Breast Cancer Res Treat, 2011 Sep 17; 131(2). PMID: 21922245    Free PMC article.
Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy.
David A L Morgan, Nicholas A Refalo, Kwok Leung Cheung.
Breast, 2010 Dec 17; 20(3). PMID: 21159509
Frailty and adherence to adjuvant hormonal therapy in older women with breast cancer: CALGB protocol 369901.
Vanessa B Sheppard, Leigh Anne Faul, +14 authors, Jeanne S Mandelblatt.
J Clin Oncol, 2014 Jun 18; 32(22). PMID: 24934786    Free PMC article.
Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures.
Lisa M Hess, Marsha A Raebel, Douglas A Conner, Daniel C Malone.
Ann Pharmacother, 2006 Jul 27; 40(7-8). PMID: 16868217
Highly Cited.
Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage.
Neetu Chawla, K Robin Yabroff, +3 authors, Joan L Warren.
Ann Epidemiol, 2014 Jul 30; 24(9). PMID: 25066409    Free PMC article.
Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet, 1998 May 30; 351(9114). PMID: 9605801
Highly Cited.
Endocrine therapy initiation from 2001 to 2008 varies by age at breast cancer diagnosis and tumor size.
Erin J Aiello Bowles, Diana S M Buist, +4 authors, Denise M Boudreau.
J Oncol Pract, 2012 Oct 19; 8(2). PMID: 23077439    Free PMC article.
NCCN Guidelines Update: Breast Cancer.
William Gradishar, Kilian E Salerno.
J Natl Compr Canc Netw, 2016 May 27; 14(5 Suppl). PMID: 27226503
Underutilization of gene expression profiling for early-stage breast cancer in California.
Rosemary D Cress, Yingjia S Chen, +2 authors, Kenneth W Kizer.
Cancer Causes Control, 2016 Apr 22; 27(6). PMID: 27097910    Free PMC article.
Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.
Arnold L Potosky, Suzanne C O'Neill, +8 authors, Marc D Schwartz.
Cancer, 2015 Aug 21; 121(22). PMID: 26291519    Free PMC article.
Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention.
Jennifer H Lin, Shumin M Zhang, JoAnn E Manson.
Cancer Prev Res (Phila), 2011 Sep 07; 4(9). PMID: 21893499
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
James L Khatcheressian, Patricia Hurley, +12 authors, American Society of Clinical Oncology.
J Clin Oncol, 2012 Nov 07; 31(7). PMID: 23129741
Highly Cited. Systematic Review.
Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer.
Larissa Nekhlyudov, Lingling Li, Dennis Ross-Degnan, Anita K Wagner.
Breast Cancer Res Treat, 2011 Aug 16; 130(2). PMID: 21842245
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Lyndsay Harris, Herbert Fritsche, +7 authors, American Society of Clinical Oncology.
J Clin Oncol, 2007 Oct 24; 25(33). PMID: 17954709
Highly Cited. Review.
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.
Michaela A Dinan, Xiaojuan Mi, +2 authors, Lesley H Curtis.
JAMA Oncol, 2015 Aug 28; 1(8). PMID: 26313372
Adjuvant hormonal therapy use among insured, low-income women with breast cancer.
Gretchen Kimmick, Roger Anderson, +3 authors, Rajesh Balkrishnan.
J Clin Oncol, 2009 May 20; 27(21). PMID: 19451445    Free PMC article.
Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States.
Philip S Rosenberg, Kimberly A Barker, William F Anderson.
J Natl Cancer Inst, 2015 Jun 13; 107(9). PMID: 26063794    Free PMC article.
Comorbidity measures for use with administrative data.
A Elixhauser, C Steiner, D R Harris, R M Coffey.
Med Care, 1998 Feb 07; 36(1). PMID: 9431328
Highly Cited.
Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.
Megan C Roberts, Stephanie B Wheeler, Katherine Reeder-Hayes.
Am J Public Health, 2015 Apr 24; 105 Suppl 3. PMID: 25905855    Free PMC article.
Systematic Review.
Improving Adherence to Adjuvant Endocrine Therapy in Breast Cancer Through a Therapeutic Educational Approach: A Feasibility Study
.
Aurélie Bourmaud, Vanessa Rousset, +7 authors, Franck Chauvin.
Oncol Nurs Forum, 2016 Apr 23; 43(3). PMID: 27105205
Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.
Caitlin C Murphy, L Kay Bartholomew, +2 authors, Sally W Vernon.
Breast Cancer Res Treat, 2012 Jun 13; 134(2). PMID: 22689091    Free PMC article.
Highly Cited. Systematic Review.
Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Dawn L Hershman, Lawrence H Kushi, +7 authors, Alfred I Neugut.
J Clin Oncol, 2010 Jun 30; 28(27). PMID: 20585090    Free PMC article.
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL).
Alfred I Neugut, Grace Clarke Hillyer, +10 authors, Dawn L Hershman.
Breast Cancer Res Treat, 2012 Apr 25; 134(1). PMID: 22527111    Free PMC article.
A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors.
Jyothi S Prabhu, Aruna Korlimarla, +12 authors, T S Sridhar.
J Cancer, 2014 Feb 25; 5(2). PMID: 24563670    Free PMC article.
Weakly hormone receptor-positive breast cancer and use of adjuvant hormonal therapy.
Cassandra M Lin, Jasbir Jaswal, +2 authors, Muriel Brackstone.
Curr Oncol, 2013 Dec 07; 20(6). PMID: 24311965    Free PMC article.
Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL).
Dawn L Hershman, Lawrence H Kushi, +10 authors, Alfred I Neugut.
Breast Cancer Res Treat, 2016 Apr 18; 157(1). PMID: 27086286    Free PMC article.
Cancer treatment and survivorship statistics, 2016.
Kimberly D Miller, Rebecca L Siegel, +6 authors, Ahmedin Jemal.
CA Cancer J Clin, 2016 Jun 03; 66(4). PMID: 27253694
Highly Cited.
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
Sunil S Badve, Frederick L Baehner, +13 authors, Joseph A Sparano.
J Clin Oncol, 2008 May 20; 26(15). PMID: 18487567
Discontinuation and non-adherence to endocrine therapy in breast cancer patients: is lack of communication the decisive factor?
P Wuensch, A Hahne, +5 authors, J Huebner.
J Cancer Res Clin Oncol, 2014 Aug 03; 141(1). PMID: 25085010
Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
P M Ravdin, L A Siminoff, +4 authors, H L Parker.
J Clin Oncol, 2001 Feb 22; 19(4). PMID: 11181660
Highly Cited.
Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
Albert J Farias, Xianglin L Du.
Med Oncol, 2016 Jan 21; 33(2). PMID: 26786154    Free PMC article.
Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors.
Heidi S Wirtz, Denise M Boudreau, +4 authors, Diana S M Buist.
Breast Cancer Res Treat, 2014 Jan 11; 143(3). PMID: 24407530    Free PMC article.
Breast cancer incidence rates in U.S. women are no longer declining.
Carol DeSantis, Nadia Howlader, Kathleen A Cronin, Ahmedin Jemal.
Cancer Epidemiol Biomarkers Prev, 2011 Mar 02; 20(5). PMID: 21357727
The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations.
Laura Panattoni, Tracy A Lieu, +5 authors, Scott D Ramsey.
Breast Cancer Res Treat, 2018 Oct 12; 173(2). PMID: 30306429    Free PMC article.